Jacqueline C. Barrientos, MD, MS

home / authors / jacqueline-c-barrientos-md-ms

Articles

Expert on CLL

Optimizing the Treatment of CLL With Novel Therapies

William G. Wierda, MD, PhD;Jacqueline C. Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO
March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

Read More

Experts on CLL

CAR T-Cell Therapies in CLL

William G. Wierda, MD, PhD;Jacqueline C. Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO
March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

Read More

Jacqueline Claudia Barrientos, MD, MS, of Northwell Health

Dr. Barrientos on the Shift Away From Chemoimmunotherapy in CLL

Jacqueline C. Barrientos, MD, MS
April 19th 2021

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Read More

Dr. Barrientos on Remaining Challenges in CLL

Dr. Barrientos on Remaining Challenges in CLL

Jacqueline C. Barrientos, MD, MS
May 24th 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses remaining challenges in the treatment of patients with chronic lymphocytic leukemia.

Read More

Latest Updated Articles

Alexis LeVee, MD
Published: May 14th 2025 | Updated: May 30th 2025
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer